News

Find News

Filter articles

Applied Filters

Showing 61 to 70 of 909 results

Novartis tries to block generic versions of Gilenya, enforces new patent

US30-01-2020Edward Pearcey

Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Fed Circuit hands win to Galderma in Teva suit

US30-01-2020Sarah Morgan

The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

US govt PrEP patents are invalid, Gilead tells court

UK27-01-2020Rory O'Neill

Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.

GSK’s Seroxat pay-for-delay deals may restrict competition: AG

EU23-01-2020Sarah Morgan

GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.

Gilead hit with antitrust suit over HIV drugs

US16-01-2020Sarah Morgan

Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

California mulls state generics brand

US13-01-2020Rory O'Neill

California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.

Judge refuses to block pay-for-delay law pending appeal

US13-01-2020Sarah Morgan

A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.

Senju, Bausch settle eye drop litigation against Indian generics maker

US09-01-2020Rory O'Neill

Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.

Fed Circuit issues mixed Sensipar verdict for Amgen

US09-01-2020Sarah Morgan

In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.

Allergan agrees to pay $300m to end birth control litigation

US08-01-2020Sarah Morgan

Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

Showing 61 to 70 of 909 results

LSIPR